Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Germline RBBP6 mutations in familial myeloproliferative neoplasms

Blood (2016) 127 (3): 362–365.

https://doi.org/10.1182/blood-2015-09-668673

Published: 2016

Includes: Supplemental data

Journal Articles

Germline RBBP6 Mutations In Myeloproliferative Neoplasms

Blood (2013) 122 (21): 267.

https://doi.org/10.1182/blood.V122.21.267.267

Published: 2013

Journal Articles

Two Cycles of ABVD Followed by Involved Field Radiotherapy with 20 Gray (Gy) Is the New Standard of Care in the Treatment of Patients with Early-Stage Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group (GHSG) HD10. Study Supported by the Deutsche Krebshilfe and in Part by the Competence Network Malignant Lymphoma.

Andreas Engert, MD, Volker Diehl, MD, Emeritus, Annette Pluetschow, Hans T. Eich, Richard Herrmann, MD, Bernd Doerken, Lothar Kanz, MD, Richard Greil, Jana Markova, Michael Fuchs, Peter Borchmann, PD, Dr., Hans Konrad Mueller-Hermelink, Rolf Peter Mueller

Blood (2009) 114 (22): 716.

https://doi.org/10.1182/blood.V114.22.716.716

Published: 2009

Journal Articles

Combined Modality Treatment with Intensified Chemotherapy and Dose-Reduced Involved Field Radiotherapy in Patients with Early Unfavourable Hodgkin Lymphoma (HL): Final Analysis of the German Hodgkin Study Group (GHSG) HD11 Trial.

Peter Borchmann, Volker Diehl, Helen Goergen, Horst Mueller, Rolf Peter Mueller, Hans T. Eich, Hans Konrad Mueller-Hermelink, Richard Herrmann, MD, Jana Markova, Anthony D. Ho, MD, PhD, Wolfgang Hiddemann, Bernd Doerken, Richard Greil, Andreas Engert, MD

Blood (2009) 114 (22): 717.

https://doi.org/10.1182/blood.V114.22.717.717

Published: 2009

Journal Articles

Radioimmunotherapy (RIT) with 177 Lutetium-DOTA-Rituximab ( 177 LU-D- R): A Phase I/II - Study in 30 Patients with Relapsing Follicular, Mantle Cell and Other Indolent B-Cell Lymphomas

Andreas Lohri, MD, Flavio Forrer, MD, PhD, Benedetta Campana, Christoph Mamot, MD, Ralph Winterhalder, MD, Richard Herrmann, MD, Helmuth R Maecke, PhD, Jan Müller-Brand, MD

Blood (2008) 112 (11): 3055.

https://doi.org/10.1182/blood.V112.11.3055.3055

Published: 2008

Journal Articles

Combined Modality Treatment of Two or Four Cycles of ABVD Followed by Involved Field Radiotherapy in the Treatment of Patients with Early Stage Hodgkin’s Lymphoma: Update Interim Analysis of the Randomised HD10 Study of the German Hodgkin Study Group (GHSG).

Andreas Engert, Annette Pluetschow, Hans T. Eich, Richard Herrmann, Bernd Doerken, Lothar Kanz, Richard Greil, Jana Markova, Beate Pfistner, Andreas Josting, Konrad Mueller-Hermelink, Ralf P. Mueller, Volker Diehl

Blood (2005) 106 (11): 2673.

https://doi.org/10.1182/blood.V106.11.2673.2673

Published: 2005

Journal Articles

Alloimmunisation of Patients Undergoing Bone Marrow Transplantation in the Setting of Leucodepleted Apheresis-Collected Single Donor Platelets.

Julie H. Crawford, MBBS, Annette Hughes, BSc, Paul K. Cannell, MBBS, Richard Herrmann, MBBS

Blood (2005) 106 (11): 962.

https://doi.org/10.1182/blood.V106.11.962.962

Published: 2005

Journal Articles

Recent Interim Analysis of the HD11 Trial of the GHSG: Intensification of Chemotherapy and Reduction of Radiation Dose in Early Unfavorable Stage Hodgkin’s Lymphoma.

Volker Diehl, Corinne Brillant, Andreas Engert, Ralf-Peter Mueller, Hans-Theodor Eich, Konrad Mueller-Hermelink, Richard Herrmann, Jana Markova, Anthony Ho, Wolfgang Hiddemann, Bernd Doerken, Richard Greil, Andreas Josting, Beate Pfistner

Blood (2005) 106 (11): 816.

https://doi.org/10.1182/blood.V106.11.816.816

Published: 2005

Journal Articles

Imatinib’s Potential Effects on Fertility, Immunity and Pulmonary Function: A Prospective Study in Patients with Previously Untreated CML.

John Francis Seymour, MBBS FRACP, Andrew Grigg, MBBS FRACP, John Reynolds, Jane Matthews, Anthony P. Schwarer, MBBS FRACP, Richard Herrmann, MBBS FRACP, Kerry McDonald Taylor, MBBS FRACP, Mark S. Hertzberg, MBBS FRACP, Anthony Mills, MBBS FRACP, Nancy Guzzo-Pernell, Michael Copeman, MBBS FRACP, Kevin Lynch, MBBS, Timothy Hughes, MBBS FRACP

Blood (2004) 104 (11): 1020.

https://doi.org/10.1182/blood.V104.11.1020.1020

Published: 2004

Journal Articles

Pamidronate Therapy for One Year after Allogeneic Bone Marrow Transplantation (AlloBMT) Reduces Bone Loss from the Lumbar Spine, Femoral Neck and Total Hip.

Andrew C. Grigg, MD, Peter Shuttleworth, RN, John Reynolds, PhD, Jeff Szer, MD, Anthony P. Schwarer, MD, Andrew W. Roberts, MD, Ken F. Bradstock, MD, Chi-Hung Hui, MD, Richard Herrmann, MD, Peter Ebeling, MD

Blood (2004) 104 (11): 2253.

https://doi.org/10.1182/blood.V104.11.2253.2253

Published: 2004

Journal Articles

Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations

Susan Branford, Zbigniew Rudzki, Ian Parkinson, Andrew Grigg, Kerry Taylor, John F. Seymour, Simon Durrant, Peter Browett, Anthony P. Schwarer, Chris Arthur, John Catalano, Michael F. Leahy, Robin Filshie, Kenneth Bradstock, Richard Herrmann, David Joske, Kevin Lynch, Tim Hughes

Blood (2004) 104 (9): 2926–2932.

https://doi.org/10.1182/blood-2004-03-1134

Published: 2004

Journal Articles

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

Susan Branford, Zbigniew Rudzki, Sonya Walsh, Ian Parkinson, Andrew Grigg, Jeff Szer, Kerry Taylor, Richard Herrmann, John F. Seymour, Chris Arthur, David Joske, Kevin Lynch, Tim Hughes

Blood (2003) 102 (1): 276–283.

https://doi.org/10.1182/blood-2002-09-2896

Published: 2003

Journal Articles

High frequency of point mutations clustered within the adenosine triphosphate–binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

Susan Branford, Zbigniew Rudzki, Sonya Walsh, Andrew Grigg, Chris Arthur, Kerry Taylor, Richard Herrmann, Kevin P. Lynch, Timothy P. Hughes

Blood (2002) 99 (9): 3472–3475.

https://doi.org/10.1182/blood.V99.9.3472

Published: 2002

NARROW

Germline RBBP6 mutations in familial myeloproliferative neoplasms

Germline RBBP6 Mutations In Myeloproliferative Neoplasms

Combined Modality Treatment with Intensified Chemotherapy and Dose-Reduced Involved Field Radiotherapy in Patients with Early Unfavourable Hodgkin Lymphoma (HL): Final Analysis of the German Hodgkin Study Group (GHSG) HD11 Trial.

Radioimmunotherapy (RIT) with 177 Lutetium-DOTA-Rituximab ( 177 LU-D- R): A Phase I/II - Study in 30 Patients with Relapsing Follicular, Mantle Cell and Other Indolent B-Cell Lymphomas

Combined Modality Treatment of Two or Four Cycles of ABVD Followed by Involved Field Radiotherapy in the Treatment of Patients with Early Stage Hodgkin’s Lymphoma: Update Interim Analysis of the Randomised HD10 Study of the German Hodgkin Study Group (GHSG).

Alloimmunisation of Patients Undergoing Bone Marrow Transplantation in the Setting of Leucodepleted Apheresis-Collected Single Donor Platelets.

Recent Interim Analysis of the HD11 Trial of the GHSG: Intensification of Chemotherapy and Reduction of Radiation Dose in Early Unfavorable Stage Hodgkin’s Lymphoma.

Imatinib’s Potential Effects on Fertility, Immunity and Pulmonary Function: A Prospective Study in Patients with Previously Untreated CML.

Pamidronate Therapy for One Year after Allogeneic Bone Marrow Transplantation (AlloBMT) Reduces Bone Loss from the Lumbar Spine, Femoral Neck and Total Hip.

Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

High frequency of point mutations clustered within the adenosine triphosphate–binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only